Actinium-225 Conjugates of MAb CC49 and Humanized ΔCH 2 CC49
Authors:
- 1 April 2002
- journal article
- research article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 17 (2) , 219-231
Abstract
Radioisotopes with moderate half-lives are essential for conventional radioimmunotherapy using tumorselective MAbs which require days for localization. Actinium-225, with a half-life of 10 days and a yield of 4 alpha particles in its decay chain, may be an ideal choice for tumor-targeted radioimmunotherapy. Release of daughter radioisotopes from the primary chelator after the first decay has been a complication with the use of 225Ac. It has been reported that the domain-deleted product of MAb CC49, Hu-ΔCH2 CC49, is able to extravasate and penetrate more deeply into tumors than the parent IgG molecule. We reasoned that once the 225Ac-chelate-MAb had penetrated into the tumor, the daughter radioisotopes would remain trapped even if they had been released from the primary chelator. Actinium-225 HEHA MAb CC49 conjugates were tested for distribution, micro-distribution and therapy in immunocompromised mice which had LS174T tumors growing at subcutaneous or intramuscular sites. Both 125I and 225Ac CC49 and Hu-ΔCH2 CC49 were efficient in delivery of the radioisotopes to tumor sites. Tissue micro-autoradiography for the two antibody forms did not demonstrate any differences in micro-distribution of either 125I or 225Ac in the tumor. Furthermore, there was no detectable difference for the two carriers in the tumor retention of daughter radioisotopes from 225Ac. Therapy experiments with 225Ac were complicated by radiotoxicity of the conjugates. The lethal dose was about 0.5 μCi in two strains of mice regardless of the carrier. At injected doses of 0.5 and 0.25 μCi, CC49 was slightly active in tumor stasis, whereas no consistent significant effect of 225Ac- Hu-ΔCH2 CC49 on growth of tumors was observed. The potential of 225Ac in radioimmunotherapy is limited by the radiotoxicity of its daughter radioisotopes. Its potential will only be realized if stable conjugates, capable of daughter radioisotope retention, can be devised.Keywords
This publication has 21 references indexed in Scilit:
- Synthesis, Conjugation, and Radiolabeling of a Novel Bifunctional Chelating Agent for 225Ac Radioimmunotherapy ApplicationsBioconjugate Chemistry, 2000
- Evaluation of 225 Ac for Vascular Targeted Radioimmunotherapy of Lung TumorsCancer Biotherapy and Radiopharmaceuticals, 2000
- Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Improved in Vivo Stability of Actinium-225 Macrocyclic ComplexesJournal of Medicinal Chemistry, 1999
- Comparison of 225actinium chelates: tissue distribution and radiotoxicityNuclear Medicine and Biology, 1999
- Radiotoxicity of Bismuth-213 Bound to Membranes of Monolayer and Spheroid Cultures of Tumor CellsRadiation Research, 1999
- Radioimmunotherapy with alpha-emitting nuclidesEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Radioimmunotherapy of Solid Tumors: A Review "Of Mice and Men"Hybridoma, 1997
- The feasibility of 225 Ac as a source of ??-particles in radioimmunotherapyNuclear Medicine Communications, 1993
- Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitterJournal of the Chemical Society, Perkin Transactions 1, 1992